ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GSK Gsk Plc

1,640.50
4.50 (0.28%)
25 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  4.50 0.28% 1,640.50 1,640.00 1,640.50 1,656.00 1,635.00 1,642.00 5,918,777 16:29:57
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.71 67.54B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,636p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £67.54 billion. Gsk has a price to earnings ratio (PE ratio) of 13.71.

Gsk Share Discussion Threads

Showing 18001 to 18023 of 33100 messages
Chat Pages: Latest  724  723  722  721  720  719  718  717  716  715  714  713  Older
DateSubjectAuthorDiscuss
23/8/2018
08:37
yes Horlicks sale will see the £17 broken, then will need to push on.
blueteam
22/8/2018
16:38
Glaxo looking very solid, good base, 17.20 in a couple of months...especially if can secure good price for Horlicks. When you look at all the total rubbish in the ftse 100, builders and such like, stands out like a beacon.
porsche1945
22/8/2018
10:53
"Still no news from USA. I thought Trump was going to make an announcement on healthcare ?"

Yep very overdue Whatsup
Perhaps some distractions , legal side, responsible?

fangorn2
21/8/2018
21:16
Still no news from USA. I thought Trump was going to make an announcement on healthcare ?
whatsup32
21/8/2018
19:07
Fangorn - they may do; very disruptive though to the remaining business as the sold bits are 'unpicked'.
alphorn
21/8/2018
19:04
That was disappointing …. not a very 'defensive' day today, was it?
tradermichael
21/8/2018
17:03
I hold roughly the same amount of RB as I do GSK. Not too certain that I would come out as a winner.
dr biotech
21/8/2018
16:22
@Alphorn,

Nah, it doesn't. Might possibly get more if they split it.
Who knows tbh

fangorn2
21/8/2018
15:05
Fangorn - doesn't look as though they want the whole lot?

(Extended my long position today).

alphorn
21/8/2018
15:01
Kellogg and Reckitt Benckiser eyeing Glaxo's consumer unit
fangorn2
21/8/2018
09:44
Magnet to 1720p, in an up channel, so far so good.
ny boy
20/8/2018
09:29
Two bits of news...

"British drugmaker GlaxoSmithKline Pharmaceuticals is working on a strategy to reduce the number of brands in India to around 20 from 130, and bring in more patented products from the parent to the country,according to Business Standard






Phama Stock Makes the Cut
One firm with a juicy yield MacDonald does like is drugmaker GlaxoSmithKline (GSK). “Historically, it just had a really good yield going for it; now we think there’s a bit more of an investment case,” she says.
That investment case is predicated on a new management team and a plan to restructure the Zovirax manufacturer. New boss Emma Walmsley is a plus, but it’s the “high-quality hire” of Hal Barron as chief science officer that is the big pull for MacDonald.
Barron has held senior positions at Genentech, Roche and Calico and is now in charge of research and development. MacDonald says: “He is already working through their pipeline to make it more efficient and focused.”
Meanwhile, his expertise in oncology, which Glaxo exited from in recent years, could signal a u-turn on that strategy. MacDonald says this would be an interesting development.
Elsewhere, the vaccines and consumer health businesses are doing well. “In time, we think all this might begin to come through in a bit more growth, which has obviously been a problem,” continues MacDonald.

fangorn2
18/8/2018
16:40
waiting to see if he gets a bung.
glasgow13
18/8/2018
16:32
Thx Fangorn. We shall have to wait. ;)
alphorn
18/8/2018
15:16
Vis trump drug pricing announcement.
It was due week just passed.

Can only find this

Drug prices: Investors are still waiting on President Trump's announcement on prescription drug prices. Ahead of the drug pricing plan reveeal, Express Scripts (NASDAQ:ESRX), Humana (NYSE:HUM), MedImpact, Optum RX and Prime Therapeutics say they have not received commitments from drug manufacturers to lower drug prices.

So it's still imminent!

fangorn2
18/8/2018
09:37
And 3 of the last 4 times it broke £16 it made £17 and the other it stopped just short.

No guarantee it will this time but very little resistance between here and there.

tim 3
18/8/2018
09:32
Care to explain doohoma3 or abdulla
whatsup32
17/8/2018
21:31
12 month closing high :-)
philanderer
17/8/2018
18:43
I think abdulla morphed into whatsup 32 also filtered
doohoma3
17/8/2018
18:25
The very welcome dividend (ignoring the special) has been 80p for 4 years now. I am contemplating a small rise after February next year (one lives in hope):-)
sicker
17/8/2018
17:13
Thanks TM . And the very best to you Sir
whatsup32
17/8/2018
16:52
Well done!
tradermichael
17/8/2018
16:48
I closed my position with a decent profit today. Very happy with GSK not so much with markets.

Good luck to holders

whatsup32
Chat Pages: Latest  724  723  722  721  720  719  718  717  716  715  714  713  Older

Your Recent History

Delayed Upgrade Clock